Roche Licenses Alector Parkinson Drug
Swiss drugmaker Roche agreed to pay up to 1.27 billion dollars to license Alectors experimental Parkinsons disease treatment. Genentech will provide 100 million upfront and handle future development.
Xurve View
Insights:
Xurve View
ALECTOR INC shares surged 72% in Monday morning premarket trading after ROCHE HOLDING AG-BR agreed to license an experimental Parkinson's disease treatment for up to $1.27 billion. The agreement expands the Switzerland-based drugmaker's neurological pipeline through an upfront payment of $100 million. The treatment targets an enzyme deficiency linked to the neurodegenerative condition.
